David Russell
Neurology · New Haven, CTNPI 1548241839
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,981 of the $207,764 with a category attached, or 65.4%. 15 manufacturers reported payments, led by Eisai Inc. at 46.0% of the total. Among neurology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $786.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$96K
- Neurocrine Biosciences, Inc.$43K
- Lilly USA, LLC$30K
- Acorda Therapeutics, Inc$13K
- GE HealthCare$9K
- Biogen$5K
- plus $13K from 9 others
Across 542 payments — averaging $57,168 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$17M
- Eli Lilly$6.3M
- Biogen$3.2M
- Roche TCRC, Inc.$2M
- Neurocrine Biosciences, Inc.$1.1M
- AbbVie$885K
- plus $561K from 4 others
What the payments were for
- Consulting fees$46,23122%
- Speaking & faculty fees$135,98165%
- Travel & lodging$17,7649%
- Food & beverage$6,1203%
- Education$1,6681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 102 | $95,502 |
| Neurocrine Biosciences, Inc. | 63 | $43,387 |
| Lilly USA, LLC | 27 | $30,215 |
| Acorda Therapeutics, Inc | 20 | $12,502 |
| GE HealthCare | 15 | $8,908 |
| Biogen | 16 | $4,540 |
| UCB SA | 4 | $3,684 |
| Teva Pharmaceuticals USA, Inc. | 4 | $3,133 |
| Adamas Pharmaceuticals, Inc. | 3 | $1,948 |
| Amneal Pharmaceuticals LLC | 2 | $1,668 |
| Jazz Pharmaceuticals Inc. | 4 | $1,556 |
| Vertex | 1 | $467 |
| Genentech USA, Inc. | 1 | $150 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
| F. Hoffmann-la Roche AG | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$207,764 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
- Marcelo MatielloNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.